Item 4 is hereby amended and supplemented as follows: On December 17, 2025, Investment Manager issued a press release containing an open letter to the Board (the "December 17 Letter") expressing its intention to nominate John Bertrand, CEO of Digital Diagnostics Inc., and Mr. Bajaj for election to the Board at the 2026 Annual Meeting of Stockholders. The foregoing description of the December 17 Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the December 17 Letter, which is filed as Exhibit 99.2 and is incorporated herein by reference. The sales of shares reported herein were undertaken for portfolio management purposes and are not an indication of the Reporting Persons' views on the future prospects of the Issuer.

Item 5(a) is hereby amended and restated in its entirety as follows: The responses of the Reporting Persons to rows (11) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. All percentages set forth herein are based upon a total of 71,733,530 shares of Common Stock outstanding as of October 31, 2025, as reported in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 5, 2025. For purposes of disclosing the number of shares of Common Stock beneficially owned by each of the Reporting Persons, Investment Manager, IMGP and Mr. Bajaj may be deemed to own beneficially (as that term is defined in Rule 13d-3 under the Act) all shares of Common Stock that are owned beneficially and directly by the Reporting Persons. Each of Investment Manager, IMGP and Mr. Bajaj disclaims beneficial ownership of such shares of Common Stock for all other purposes.

Item 5(b) is hereby amended and restated in its entirety as follows: The responses of the Reporting Persons to rows (7) through (10) of the cover pages of this Schedule 13D are incorporated herein by reference.

Item 5(c) is hereby amended and restated in its entirety as follows: Information concerning transactions in the shares of Common Stock effected by the Reporting Persons during the past sixty days is set forth in Schedule A hereto and is incorporated herein by reference.

Item 5(d) is hereby amended and restated in its entirety as follows: No persons other than the Reporting Persons, Osprey and the Separately Managed Accounts are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Schedule 13D that may be deemed to be beneficially owned by the Reporting Persons.

Item 5(e) is hereby amended and restated in its entirety as follows: Not applicable.

Item 7 is hereby amended and supplemented as follows: Exhibit 99.2: December 17 Letter